title: [Clinical study of post-operative adjuvant chemotherapy in non-small cell lung cancer].
abstract: BACKGROUND
  Post-operative adjuvant chemotherapy in non-small cell lung can- cer (NSCLC) has been a highlight around the world. The aim of this study is to investigate the efficacy of adjuvant chemotherapy on the survival of patients with NSCLC after complete resection.
  
  
  METHODS
  From June 2000 to December 2003, 64 patients with stage IB-IIIA NSCLC were divided into the chemotherapy group, who accepted adjuvant chemotherapy with navelbine+cisplatin (NP) or taxol+carboplatin (TP), and the observation group, who did not accept adjuvant chemotherapy after operation. The 1-, 2-, 3- and 4-year survival rate (SR), median survival time (MST) and disease-free time (DFT) were analyzed by Kaplan-Meier method.
  
  
  RESULTS
  The 1-, 2-, 3- and 4-year cumulated SR in the chemotherapy group was 93.9%, 84.6%, 71.4% and 58.4%, and 93.6%, 83.1%, 63.5% and 43.1% in the observation group respectively. There were statistically significant differences in both the 3- and 4-year survival between the two groups (P < 0.05). The MST was 52 months in the chemotherapy group and 47 months in the observation group respectively (P < 0.05), and the DFT was 19 months and 16 months respectively (P < 0.05).
  
  
  CONCLUSIONS
  The cisplatin- or carboplatin-based adjuvant chemotherapy can improve the survival of NSCLC patients after complete resection.
authors.affiliation: Department of Thoracic Surgery, Navy General Hospital, PLA, Beijing 100037, P.R.China.
authors.forename: Weian
authors.initials: W
authors.lastname: Song
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Liqun
authors.initials: L
authors.lastname: Shang
authors.forename: Feng
authors.initials: F
authors.lastname: Wen
authors.forename: Jun
authors.initials: J
authors.lastname: Li